Natco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalidomide. This led to a pronounced drop in consolidated revenues compared to the prior year. On a brighter note, the core business showed some positive growth, and total expenses saw a decrease, providing a silver lining to the financial report.
Natco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalidomide. This led to a pronounced drop in consolidated revenues compared to the prior year. On a brighter note, the core business showed some positive growth, and total expenses saw a decrease, providing a silver lining to the financial report.
<iframe src="https://hindustansphere.com/embed/cluster/4f175cc861bc3fef7142836584c685e46583d1ec" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Natco Pharma Q1 profit falls 57 pc to Rs 206.5 cr"></iframe>
